However, as indicated by Kim et al., the clinical development of the TGF-β pathway antagonists faces significant challenges, mainly focused on minimizing unintended interference with tumor-suppressing functions and inflammatory responses [217]. This evidence concerns the gene TGFB1 and neoplasm.